alendronate and prednisone

alendronate has been researched along with prednisone in 25 studies

Research

Studies (25)

TimeframeStudies, this research(%)All Research%
pre-19900 (0.00)18.7374
1990's3 (12.00)18.2507
2000's13 (52.00)29.6817
2010's8 (32.00)24.3611
2020's1 (4.00)2.80

Authors

AuthorsStudies
Benz, RD; Contrera, JF; Kruhlak, NL; Matthews, EJ; Weaver, JL1
Chen, M; Hu, C; Suzuki, A; Thakkar, S; Tong, W; Yu, K1
Cappiello, V; Cepollaro, C; Gennari, C; Gonnelli, S; Pondrelli, C; Rottoli, P; Vagliasindi, M1
Brown, JP; Czachur, M; Daifotis, AG; Delmas, PD; Emkey, R; Goemaere, S; Hawkins, F; Liberman, UA; Malice, MP; Saag, KG; Schnitzer, TJ; Thamsborg, G1
Fallon, JJ; Goldstein, MF; Harning, R1
Chidambaran, P; Ettinger, B; Pressman, A1
Bertin, P; Inaoui, R; Jaccard, A; Petit, B; Trèves, R1
Czachur, M; Daifotis, AG; Delmas, PD; Emkey, R; Goemaere, S; Liberman, UA; Lombardi, A; Poubelle, PE; Verbruggen, N1
Jeffery, JR; Karpinski, ME; Leslie, WD; Nickerson, PW; Rush, DN1
Chun, CS1
Dejardin, A; Devogelaer, JP; Goffin, E1
Cundy, T; Hailwood, S; Horne, A; Lucas, J; Rudge, S; Wu, F1
Ambler, GR; Chaitow, J; McDonald, DW; Ouvrier, RA; Rogers, M1
Bijlsma, JW; Dijkmans, BA; Geusens, P; Lems, WF; Lips, P; Lodder, MC; Schrameijer, N; van de Ven, CM1
Papierska, L; Rabijewski, M1
Di Comite, G; Rossi, CM1
Li, Q; Shi, C; Zou, X1
Crozier, J; Massasso, D; Sharma, P; Tsai, TY1
Aneiros-Cachaza, J; Aneiros-Fernandez, J; Arias-Santiago, S; Husein-Elahmed, H; Naranjo-Sintes, R1
Fett, N; Liu, RH1
Koubar, S; Mahmood, K; Ninan, NA; Shofer, SL; Wahidi, MM1
Blaeser, A; Bollinger, LE; Cox, MD; Harper, AD; Lu, P; Lu, QL; Luckie, TM; Madden, KL; Richardson, SM; Shah, SN; Sparks, S; Sun, Y; Wu, B1
Agnusdei, D; Alam, J; Hans, D; Kohlmeier, LA; Krohn, KD; Leib, ES; MacLaughlin, EJ; Marcus, R; Saag, KG; Simonelli, C; Taylor, KA1
Goh, TL; Kendrick-Jones, J1
Biver, E; Caruso, A; Fayolle, D; Lefeuvre, L1

Reviews

5 review(s) available for alendronate and prednisone

ArticleYear
DILIrank: the largest reference drug list ranked by the risk for developing drug-induced liver injury in humans.
    Drug discovery today, 2016, Volume: 21, Issue:4

    Topics: Chemical and Drug Induced Liver Injury; Databases, Factual; Drug Labeling; Humans; Pharmaceutical Preparations; Risk

2016
Chronic glucocorticoid therapy-induced osteoporosis in patients with obstructive lung disease.
    Chest, 1999, Volume: 116, Issue:6

    Topics: Administration, Inhalation; Administration, Oral; Adult; Alendronate; Asthma; Bone Density; Bone Remodeling; Calcitonin; Clodronic Acid; Etidronic Acid; Fluorides; Glucocorticoids; Hormone Replacement Therapy; Humans; Lung Diseases, Obstructive; Osteoporosis; Prednisone; Time Factors

1999
Chronic recurrent multifocal osteomyelitis of the spine and mandible: case report and review of the literature.
    Pediatrics, 2004, Volume: 113, Issue:4

    Topics: Alendronate; Anti-Bacterial Agents; Anti-Inflammatory Agents, Non-Steroidal; Child, Preschool; Chronic Disease; Female; Humans; Interferon-gamma; Lumbar Vertebrae; Magnetic Resonance Imaging; Mandibular Diseases; Osteomyelitis; Pain; Prednisone; Recurrence; Spinal Diseases

2004
[Glucocorticoid-induced osteoporosis].
    Polskie Archiwum Medycyny Wewnetrznej, 2007, Volume: 117, Issue:8

    Topics: Alendronate; Bone Density; Bone Density Conservation Agents; Calcium; Diphosphonates; Female; Fractures, Spontaneous; Glucocorticoids; Humans; Male; Osteomalacia; Osteoporosis; Parathyroid Hormone; Prednisone; Selective Estrogen Receptor Modulators; Spinal Fractures; Vitamin D

2007
Multicentric reticulohistiocytosis with dermatomyositis-like features: a more common disease presentation than previously thought.
    Dermatology (Basel, Switzerland), 2011, Volume: 222, Issue:2

    Topics: Alendronate; Antineoplastic Protocols; Arthritis; Breast Neoplasms; Combined Modality Therapy; Dermatologic Agents; Dermatomyositis; Diagnosis, Differential; Drug Therapy, Combination; Female; Histiocytosis; Humans; Lymphatic Metastasis; Mediastinal Neoplasms; Methotrexate; Middle Aged; Prednisone

2011

Trials

8 trial(s) available for alendronate and prednisone

ArticleYear
Prevention of corticosteroid-induced osteoporosis with alendronate in sarcoid patients.
    Calcified tissue international, 1997, Volume: 61, Issue:5

    Topics: Absorptiometry, Photon; Adult; Aged; Alendronate; Analysis of Variance; Anti-Inflammatory Agents; Biomarkers; Bone Density; Female; Humans; Male; Middle Aged; Osteoporosis; Prednisone; Sarcoidosis; Thoracic Diseases

1997
Alendronate for the prevention and treatment of glucocorticoid-induced osteoporosis. Glucocorticoid-Induced Osteoporosis Intervention Study Group.
    The New England journal of medicine, 1998, Jul-30, Volume: 339, Issue:5

    Topics: Adolescent; Aged; Aged, 80 and over; Alendronate; Bone Density; Double-Blind Method; Female; Glucocorticoids; Humans; Male; Middle Aged; Osteoporosis; Prednisone; Risk Factors; Spinal Fractures

1998
Changes in bone mineral density following discontinuation or continuation of alendronate therapy in glucocorticoid-treated patients: a retrospective, observational study.
    Arthritis and rheumatism, 2003, Volume: 48, Issue:4

    Topics: Adult; Aged; Alendronate; Bone Density; Dose-Response Relationship, Drug; Drug Administration Schedule; Drug Therapy, Combination; Glucocorticoids; Hip; Humans; Lumbar Vertebrae; Middle Aged; Osteoporosis; Prednisone; Radiography; Retrospective Studies; Treatment Outcome

2003
Prevalence and treatment of decreased bone density in renal transplant recipients: a randomized prospective trial of calcitriol versus alendronate.
    Transplantation, 2003, Nov-27, Volume: 76, Issue:10

    Topics: Adult; Alendronate; Azathioprine; Bone Density; Bone Resorption; Calcitriol; Calcium Channel Agonists; Cross-Sectional Studies; Cyclosporine; Female; Humans; Immunosuppression Therapy; Kidney Transplantation; Male; Middle Aged; Mycophenolic Acid; Postoperative Complications; Prednisone

2003
Effects of once-weekly oral alendronate on bone in children on glucocorticoid treatment.
    Rheumatology (Oxford, England), 2005, Volume: 44, Issue:6

    Topics: Administration, Oral; Adolescent; Alendronate; Arthritis, Juvenile; Body Height; Bone Density; Bone Resorption; Child; Child, Preschool; Collagen; Collagen Type I; Dermatomyositis; Double-Blind Method; Drug Administration Schedule; Female; Femur; Glucocorticoids; Humans; Lumbar Vertebrae; Lupus Erythematosus, Systemic; Male; Peptides; Prednisone; Stress, Mechanical

2005
Positive effect of alendronate on bone mineral density and markers of bone turnover in patients with rheumatoid arthritis on chronic treatment with low-dose prednisone: a randomized, double-blind, placebo-controlled trial.
    Osteoporosis international : a journal established as result of cooperation between the European Foundation for Osteoporosis and the National Osteoporosis Foundation of the USA, 2006, Volume: 17, Issue:5

    Topics: Absorptiometry, Photon; Alendronate; Alkaline Phosphatase; Analysis of Variance; Arthritis, Rheumatoid; Bone Density; Bone Density Conservation Agents; Bone Remodeling; Collagen Type I; Double-Blind Method; Female; Glucocorticoids; Hip; Humans; Lumbar Vertebrae; Male; Middle Aged; Peptides; Prednisone

2006
[Effect of alendronate on glucocorticoid-induced osteoporosis].
    Zhong nan da xue xue bao. Yi xue ban = Journal of Central South University. Medical sciences, 2009, Volume: 34, Issue:6

    Topics: Adult; Alendronate; Bone Density; Bone Density Conservation Agents; Female; Humans; Male; Middle Aged; Osteoporosis; Prednisone; Rheumatic Fever

2009
Trabecular Bone Score in Patients With Chronic Glucocorticoid Therapy-Induced Osteoporosis Treated With Alendronate or Teriparatide.
    Arthritis & rheumatology (Hoboken, N.J.), 2016, Volume: 68, Issue:9

    Topics: Alendronate; Bone Density Conservation Agents; Cancellous Bone; Chronic Disease; Double-Blind Method; Female; Glucocorticoids; Humans; Male; Middle Aged; Osteoporosis; Prednisone; Teriparatide

2016

Other Studies

12 other study(ies) available for alendronate and prednisone

ArticleYear
Assessment of the health effects of chemicals in humans: II. Construction of an adverse effects database for QSAR modeling.
    Current drug discovery technologies, 2004, Volume: 1, Issue:4

    Topics: Adverse Drug Reaction Reporting Systems; Artificial Intelligence; Computers; Databases, Factual; Drug Prescriptions; Drug-Related Side Effects and Adverse Reactions; Endpoint Determination; Models, Molecular; Quantitative Structure-Activity Relationship; Software; United States; United States Food and Drug Administration

2004
Prevalence and determinants of osteoporosis drug prescription among patients with high exposure to glucocorticoid drugs.
    The American journal of managed care, 2001, Volume: 7, Issue:6

    Topics: Adult; Aged; Alendronate; Calcitonin; California; Drug Prescriptions; Drug Utilization Review; Etidronic Acid; Female; Glucocorticoids; Humans; Male; Middle Aged; Osteoporosis; Prednisone

2001
Aggressive systemic mastocytosis.
    Joint bone spine, 2003, Volume: 70, Issue:1

    Topics: Aged; Alendronate; Bone Marrow Cells; Fatal Outcome; Female; Humans; Interferon-alpha; Leukemia, Myeloid, Acute; Mast Cells; Mast-Cell Sarcoma; Mastocytosis, Systemic; Neoplasms, Multiple Primary; Osteoporosis, Postmenopausal; Prednisone; Serine Endopeptidases; Tryptases

2003
Alendronate versus calcitriol for prevention of bone loss after cardiac transplantation.
    The New England journal of medicine, 2004, May-27, Volume: 350, Issue:22

    Topics: Alendronate; Bone Density; Bone Resorption; Calcitriol; Creatinine; Cyclosporine; Female; Heart Transplantation; Humans; Immunosuppression Therapy; Immunosuppressive Agents; Male; Prednisone; Renal Insufficiency; Tacrolimus

2004
Rapid improvement of calcinosis in juvenile dermatomyositis with alendronate therapy.
    The Journal of rheumatology, 2005, Volume: 32, Issue:9

    Topics: Alendronate; Calcinosis; Child; Dermatomyositis; Dose-Response Relationship, Drug; Drug Administration Schedule; Drug Therapy, Combination; Follow-Up Studies; Humans; Male; Methotrexate; Prednisone; Radiography; Risk Assessment; Severity of Illness Index; Treatment Outcome

2005
Teriparatide or alendronate in glucocorticoid-induced osteoporosis.
    The New England journal of medicine, 2008, Mar-20, Volume: 358, Issue:12

    Topics: Alendronate; Bone Density; Bone Density Conservation Agents; Glucocorticoids; Humans; Osteoporosis; Prednisone; Teriparatide

2008
Taking PET for a walk - an unusual cause of bilateral leg claudication.
    The Journal of rheumatology, 2010, Volume: 37, Issue:4

    Topics: Alendronate; Anti-Inflammatory Agents; Aspirin; Drug Therapy, Combination; Female; Giant Cell Arteritis; Humans; Intermittent Claudication; Middle Aged; Prednisone; Radionuclide Imaging; Treatment Outcome

2010
Lichenoid dermatosis induced by alendronate: an unusual skin drug reaction.
    Acta dermato-venereologica, 2010, Volume: 90, Issue:3

    Topics: Aged; Alendronate; Biopsy; Bone Density Conservation Agents; Glucocorticoids; Humans; Lichenoid Eruptions; Lumbar Vertebrae; Male; Osteoporosis; Prednisone; Skin; Spinal Fractures; Treatment Outcome

2010
Alendronate tracheobronchitis.
    Annals of the American Thoracic Society, 2013, Volume: 10, Issue:1

    Topics: Alendronate; Anti-Bacterial Agents; Anti-Inflammatory Agents; Biopsy; Bone Density Conservation Agents; Bronchitis; Bronchoscopy; Debridement; Female; Humans; Middle Aged; Osteoporosis; Prednisone; Respiratory System; Tracheitis; Treatment Outcome

2013
Glucocorticoid Steroid and Alendronate Treatment Alleviates Dystrophic Phenotype with Enhanced Functional Glycosylation of α-Dystroglycan in Mouse Model of Limb-Girdle Muscular Dystrophy with FKRPP448L Mutation.
    The American journal of pathology, 2016, Volume: 186, Issue:6

    Topics: Adrenal Cortex Hormones; Alendronate; Animals; Blotting, Western; Bone Density; Bone Density Conservation Agents; Dystroglycans; Glycosylation; Mice; Mice, Mutant Strains; Muscle, Skeletal; Muscular Dystrophies, Limb-Girdle; Muscular Dystrophy, Animal; Phenotype; Prednisone

2016
Alendronate sodium-induced interstitial nephritis.
    Internal medicine journal, 2017, Volume: 47, Issue:11

    Topics: Alendronate; Bone Density Conservation Agents; Creatinine; Female; Humans; Middle Aged; Nephritis, Interstitial; Prednisone

2017
Orbital myositis induced by alendronate: A case report.
    European journal of neurology, 2023, Volume: 30, Issue:6

    Topics: Aged; Alendronate; Diphosphonates; Female; Humans; Orbital Myositis; Osteoporosis; Prednisone

2023